On 20. July 2026 PolyPeptide Group AG (PolyPeptide) and Samsung Biologics Co., Ltd. (Samsung Biologics), a leading global CDMO, announced that they have entered into a transaction agreement under which Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 per share. The offer values PolyPeptide’s equity at approximately CHF 1.46 billion. The transaction aims to provide PolyPeptide with the resources, investment capacity and strategic platform to pursue the next phase of its growth and innovation. Alongside Samsung Biologics’ global manufacturing scale and track record of operational excellence, PolyPeptide will also benefit from an aligned customer footprint. IFBC prepared an independent Fairness Opinion for the Board of Directors of PolyPeptide to assess the financial fairness of the public takeover offer of CHF 44.31 per PolyPeptide share.
